COMP <GO>
UTMD vs MRK // ENTERPRISE SCALE & MARKET CAP
Utah Medical Products Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: UTMD 3
— MRK 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $66.80 (-2.96%) • MKT CAP: $212.7M
market-cap
$212.7M
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTMD VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTMD | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.10% | 74.80% | -17.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.90% | 20.70% | +6.20 | UTMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.8x | 15.3x | -4.50 | UTMD | /valuation <GO> |
| Free Cash Flow Yield | 6.73% | 3.42% | +3.31 | UTMD | /fcf-yield <GO> |
| Operating Margin | 29.60% | 34.30% | -4.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | — | 28.10% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -5.80% | 1.30% | -7.10 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.87% | 2.26% | -0.39 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.2 | 51.7 | -24.50 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $212.7M | $361.02B | -$360.81B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTMD REV | MRK REV | UTMD GROSS % | MRK GROSS % | UTMD FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.5M | $65.01B | 57.1% | 74.8% | $14.3M | $12.36B |
| FY 2024 | $40.9M | $64.17B | 59.0% | 76.3% | $14.6M | $18.10B |
| FY 2023 | $50.2M | $60.12B | — | — | $22.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTMD // BETA —
MRK // BETA 0.92